Search

Your search keyword '"Lior Gepstein"' showing total 196 results

Search Constraints

Start Over You searched for: Author "Lior Gepstein" Remove constraint Author: "Lior Gepstein"
196 results on '"Lior Gepstein"'

Search Results

1. The role of genetic testing in the prevention, diagnosis, and prognosis of sudden cardiac arrest in children

2. Synthetic cells with self-activating optogenetic proteins communicate with natural cells

3. Characterization of the mechanism by which a nonsense variant in RYR2 leads to disordered calcium handling

4. Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes

5. Optogenetic Control of Human Induced Pluripotent Stem Cell‐Derived Cardiac Tissue Models

6. Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors

8. Optogenetic modulation of cardiac action potential properties may prevent arrhythmogenesis in short and long QT syndromes

9. Type of Anemia, Chronic Non-cardiovascular Illnesses, and Outcomes of Patients with ST-segment Elevation Myocardial Infarction

10. Modeling Atrial Fibrillation using Human Embryonic Stem Cell-Derived Atrial Tissue

11. Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters

12. Uncovering the Role of Hypermethylation by CTG Expansion in Myotonic Dystrophy Type 1 Using Mutant Human Embryonic Stem Cells

13. The Third Intron of the Interferon Regulatory Factor-8 Is an Initiator of Repressed Chromatin Restricting Its Expression in Non-Immune Cells.

14. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes.

16. Redifferentiated cardiomyocytes retain residual dedifferentiation signatures and are protected against ischemic injury

18. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

19. Elevated thrombin generation levels in the left atrial appendage in patients with atrial fibrillation

22. shRNAs Targeting a Common KCNQ1 Variant Could Alleviate Long-QT1 Disease Severity by Inhibiting a Mutant Allele

23. Redifferentiated cardiomyocytes retain residual dedifferentiation signatures and are protected against ischaemic injury

24. Factors Associated with Left Ventricular Function Recovery in Patients with Atrial Fibrillation Related Cardiomyopathy

25. Study and modulation of cardiac electroporation with a novel model utilizing human induced pluripotent stem cells

26. Isolated superfused rats atrial model for the investigation of atrial fibrillation mechanisms and treatment

27. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation

28. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications

29. Bioluminescent Synthetic Cells Communicate with Natural Cells and Self-Activate Light-Responsive Proteins

30. Non-ischemic sudden cardiac arrest: Role of 12 lead Holter, family screening and genetic testing

31. Characterisation of the mechanism by which a nonsense variant in RYR2 results in ventricular arrhythmia

32. Using Decellularization/Recellularization Processes to Prepare Liver and Cardiac Engineered Tissues

33. Titin circular RNAs create a back-splice motif essential for SRSF10 splicing

34. Using Decellularization/Recellularization Processes to Prepare Liver and Cardiac Engineered Tissues

38. Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis

39. Small extracellular vesicles from epicardial fat of patients with atrial fibrillation induce inflammation, fibrosis and re-entrant arrhythmias

40. Measuring the systolic and the diastolic properties of single human pluripotent stem-cell cardiomyocyte for drug testing and disease modeling

41. Reply to 'Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?'

42. Type of Anemia, Chronic Non-cardiovascular Illnesses, and Outcomes of Patients with ST-segment Elevation Myocardial Infarction

43. Robust fabrication of composite 3D scaffolds with tissue-specific bioactivity : a proof-of-concept study

44. Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes

46. Thyroid and Dexamethasone Treatment Enhances the Expression of Repolarizing Potassium Currents and Improve Electrophysiological Maturation of Human IPSC-Derived Cardiomyocytes

47. Optogenetic Neuromodulation of the Heart

48. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing

49. Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association

50. Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies

Catalog

Books, media, physical & digital resources